Roche abandons its hostile takeover bid for Illumina
Swiss drug giant Roche has abandoned its hostile takeover bid for gene sequencing firm Illumina.
SAN DIEGO - Illumina urged its shareholders Monday to reject a sweetened buyout offer from the Swiss drugmaker Roche, saying that the $6.5 billion deal still undervalues the California maker of genetic analysis instruments.